RT Journal Article SR Electronic T1 Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn’s disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.19.20070995 DO 10.1101/2020.04.19.20070995 A1 Potdar, Alka A. A1 Dube, Shishir A1 Naito, Takeo A1 Botwin, Gregory A1 Haritunians, Talin A1 Li, Dalin A1 Yang, Shaohong A1 Bilsborough, Janine A1 Denson, Lee A. A1 Daly, Mark A1 Targan, Stephan R. A1 Fleshner, Phillip A1 Braun, Jonathan A1 Kugathasan, Subra A1 Stappenbeck, Thaddeus S. A1 McGovern, Dermot P.B. YR 2020 UL http://medrxiv.org/content/early/2020/04/23/2020.04.19.20070995.abstract AB Angiotensin-Converting Enzyme 2 (ACE2) has been identified as the host receptor for SARS-coronavirus 2 (SARS-CoV-2) which has infected millions world-wide and likely caused hundreds of thousands of deaths. Utilizing transcriptomic data from four cohorts taken from Crohn’s disease (CD) and non-inflammatory bowel disease (IBD) subjects, we observed evidence of increased ACE2 mRNA in ileum with demographic features that have been associated with poor outcomes in COVID-19 including age and raised BMI. ACE2 was downregulated in CD compared to controls in independent cohorts. Within CD, ACE2 expression was reduced in inflamed ileal tissue and also remarkably, from un-involved tissue in patients with a worse prognosis in both adult and pediatric cohorts. In active CD, small bowel ACE2 expression was restored by anti-TNF therapy particularly in anti-TNF responders. Collectively our data suggest that ACE2 downregulation is associated with inflammation and worse outcomes in CD.Competing Interest StatementCedars-Sinai has financial interests in Prometheus Biosciences, Inc., a company which has access to the data and specimens in Cedars-Sinai’s MIRIAD Biobank (including the data and specimens used in this study) and seeks to develop commercial products. DPBM, JB, SRT own stock in Prometheus Biosciences Inc. AAP, DL, JB, SRT, DPBM are consultants for Prometheus Biosciences, Inc. DPBM has consulted for Gilead, Pfizer, Boehringer Ingelheim, Qu Biologics, Bridge Biotherapeutics, and received grant support from Janssen. TSS has consulted for Janssen, Boehringer Ingelheim, Genentech and Takeda.Funding StatementThis work was supported by internal funds from the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute. The Cedars-Sinai MIRIAD IBD Biobank is supported by the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [NIH/NIDDK] [grants P01 DK046763 and U01 DK062413], and The Leona M and Harry B Helmsley Charitable Trust.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTranscriptomics datasets used in this manuscript are available on public dataset (GEO, Accession #s: GSE120782, GSE57945, GSE16879,GSE100833). One is available at arrayExpress (E-MTAB-5783). One of the dataset is unpublished and will be deposited on GEO.